CoChat

The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges

Open access
Naidoo, Pren, Theron, Grant, Rangaka, Molebogeng X, Chihota, Violet N, Vaughan, Louise, Brey, Zameer O, Pillay, Yogan · 2017 · The Journal of Infectious Diseases

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

Background: While tuberculosis incidence and mortality are declining in South Africa, meeting the goals of the End TB Strategy requires an invigorated programmatic response informed by accurate data. Enumerating the losses at each step in the care cascade enables appropriate targeting of interventions and resources. Methods: We estimated the tuberculosis burden; the number and proportion of individuals with tuberculosis who accessed tests, had tuberculosis diagnosed, initiated treatment, and successfully completed treatment for all tuberculosis cases, for those with drug-susceptible tuberculosis (including human immunodeficiency virus (HIV)-coinfected cases) and rifampicin-resistant tuberculosis. Estimates were derived from national electronic tuberculosis register data, laboratory data, and published studies. Results: The overall tuberculosis burden was estimated to be 532005 cases (range, 333760-764480 cases), with successful completion of treatment in 53% of cases. Losses occurred at multiple steps: 5% at test access, 13% at diagnosis, 12% at treatment initiation, and 17% at successful treatment completion. Overall losses were similar among all drug-susceptible cases and those with HIV coinfection (54% and 52%, respectively, successfully completed treatment). Losses were substantially higher among rifampicin- resistant cases, with only 22% successfully completing treatment. Conclusion: Although the vast majority of individuals with tuberculosis engaged the public health system, just over half were successfully treated. Urgent efforts are required to improve implementation of existing policies and protocols to close gaps in tuberculosis diagnosis, treatment initiation, and successful treatment completion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/infdis/jix335

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Estimated tuberculosis incidence and mortality in South Africa and projected sustainable development goals and End TB Strategy targets. Data on the estimated tuberculosis incidence rates and mortality for 2000 to 2015 are from the revised time series analysis of global tuberculosis burden published by the World Health Organization in 2016 [4]. Projected figures for 2030–2035 are based on targets relative to the 2015 estimates and assume a straight-line decline in tuberculosis incidence rates and mortality in this period.
Figure 1. Estimated tuberculosis incidence and mortality in South Africa and projected sustainable development goals and End TB Strategy targets. Data on the estimated tuberculosis incidence rates and mortality for 2000 to 2015 are from the revised time series analysis of global tuberculosis burden published by the World Health Organization in 2016 [4]. Projected figures for 2030–2035 are based on targets relative to the 2015 estimates and assume a straight-line decline in tuberculosis incidence rates and mortality in this period.CC BY · PubMed Central
Figure 2. Approach to estimating the number of cases at each step in the tuberculosis care cascade. Abbreviations: DS, drug susceptible; HIV, human immunodeficiency virus; RIF-R, rifampicin resistant; WHO, World Health Organization.
Figure 2. Approach to estimating the number of cases at each step in the tuberculosis care cascade. Abbreviations: DS, drug susceptible; HIV, human immunodeficiency virus; RIF-R, rifampicin resistant; WHO, World Health Organization.CC BY · PubMed Central
Figure 3. Care cascade for all patients with tuberculosis. This cascade includes patients with drug-susceptible tuberculosis and with all types of rifampicin-resistant tuberculosis. The wide confidence interval for the tuberculosis burden reflects the World Health Organisation incidence estimates for South Africa, which are based on case notification data and expert opinion on case detection gaps. The proportion at each step of the cascade is expressed in relation to the estimated burden.
Figure 3. Care cascade for all patients with tuberculosis. This cascade includes patients with drug-susceptible tuberculosis and with all types of rifampicin-resistant tuberculosis. The wide confidence interval for the tuberculosis burden reflects the World Health Organisation incidence estimates for South Africa, which are based on case notification data and expert opinion on case detection gaps. The proportion at each step of the cascade is expressed in relation to the estimated burden.CC BY · PubMed Central
Figure 4. Care cascade for patients with drug-susceptible (DS) tuberculosis. The proportion at each step of the cascade is expressed in relation to the estimated burden.
Figure 4. Care cascade for patients with drug-susceptible (DS) tuberculosis. The proportion at each step of the cascade is expressed in relation to the estimated burden.CC BY · PubMed Central
Figure 5. Care cascade for human immunodeficiency virus (HIV) co-infected patients with drug-susceptible (DS) tuberculosis. The proportion at each step of the cascade is expressed in relation to the estimated burden.
Figure 5. Care cascade for human immunodeficiency virus (HIV) co-infected patients with drug-susceptible (DS) tuberculosis. The proportion at each step of the cascade is expressed in relation to the estimated burden.CC BY · PubMed Central
Figure 6. Care cascade for patients with rifampicin-resistant (RIF-R) tuberculosis. The RIF-R tuberculosis burden has a wide confidence interval, reflecting a multiplier effect when both the confidence intervals for the tuberculosis burden for all patients (derived from World Health Organization incidence estimates) and the proportion with RIF-R tuberculosis (from the national drug-resistant tuberculosis prevalence survey) are taken into account. The cascade reflects all patients with RIF-R tuberculosis (including monoresistant, multidrug-resistant, pre–extensively drug-resistant, and extensively drug-resistant tuberculosis). The proportion at each step of the cascade is expressed in relation to the estimated burden.
Figure 6. Care cascade for patients with rifampicin-resistant (RIF-R) tuberculosis. The RIF-R tuberculosis burden has a wide confidence interval, reflecting a multiplier effect when both the confidence intervals for the tuberculosis burden for all patients (derived from World Health Organization incidence estimates) and the proportion with RIF-R tuberculosis (from the national drug-resistant tuberculosis prevalence survey) are taken into account. The cascade reflects all patients with RIF-R tuberculosis (including monoresistant, multidrug-resistant, pre–extensively drug-resistant, and extensively drug-resistant tuberculosis). The proportion at each step of the cascade is expressed in relation to the estimated burden.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 7

  1. World Health Organization (WHO), 2016, Global tuberculosis report 2016
  2. South African National Institute for Communicable Diseases, 2016, South African tuberculosis drug-resistance survey 2012–14
  3. World Health Organization, 2015, The End TB Strategy
  4. World Health Organization, 2009, TB impact measurement policy and recommendations for how to assess the epidemiological burden of TB and the impact of TB control
  5. Glaziou, 2012, Methods used to estimate the global burden of disease caused by TB
  6. World Health Organization (WHO), 2016, WHO treatment guidelines for drug-resistant tuberculosis
  7. Health Systems Trust, 2015, District health barometer 2014/2015

Cited by

See all 238

Metadata

Authors
Naidoo, P., Theron, G., Rangaka, M. X., Chihota, V. N., Vaughan, L., Brey, Z. O., & Pillay, Y.
Affiliations
  • Gates Foundation (US)
  • Stellenbosch University (ZA)
  • University of Cape Town (ZA)
  • University of the Witwatersrand (ZA)
  • Department of Health (ZA)
Corresponding author
Naidoo, Pren
Venue
The Journal of Infectious Diseases
Published
2017-10-01
Volume
216
Issue
suppl_7
Pages
S702-S713
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2767345805
Cited by
238
References
54
Citations by year
2026: 11 · 2025: 13 · 2024: 26 · 2023: 23 · 2022: 32 · 2021: 38 · 2020: 43 · 2019: 32 · 2018: 18 · 2017: 2
FWCI
20.00
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • The Journal of Infectious Diseases (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • United States Agency for International Development (AIDOAAA1000021)
  • Bill and Melinda Gates Foundation
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
Keywords
treatment completion, rifampicin-resistant tuberculosis, HIV/TB coinfection, drug-susceptible tuberculosis, tuberculosis diagnosis, treatment initiation, End TB Strategy, South Africa
MeSH terms
Antibiotics, Antitubercular, Antitubercular Agents, Community Health Services, Patient Care, Humans, Mycobacterium tuberculosis, Rifampin, South Africa, Tuberculosis, HIV Infections, Incidence, Treatment Outcome, Cost of Illness, Tuberculosis, Multidrug-Resistant, Drug Resistance, Multiple, Bacterial, Black People, Lost to Follow-Up, Coinfection, Disease Eradication

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.